Evidence map›Paper›PMID 42585014›Full record

ArticleSTAR protocols2026

Protocol for in vitro profiling of key TNF downstream signaling pathways involved in cell death and pro-survival signaling in cancer cells.

Laura Unmuth, Britta Lipinski, Julia Harwardt, Lukas Pekar, Stefan Zielonka

Abstract read
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura UnmuthAntibody Discovery and Protein Engineering (ADPE), Merck Healthcare KGaA, Darmstadt, Germany; Biomolecular Immunotherapy, Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany. Electronic address: laura.unmuth@merckgroup.com.
Britta LipinskiAntibody Discovery and Protein Engineering (ADPE), Merck Healthcare KGaA, Darmstadt, Germany; Biomolecular Immunotherapy, Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
Julia HarwardtAntibody Discovery and Protein Engineering (ADPE), Merck Healthcare KGaA, Darmstadt, Germany.
Lukas PekarAntibody Discovery and Protein Engineering (ADPE), Merck Healthcare KGaA, Darmstadt, Germany.
Stefan ZielonkaAntibody Discovery and Protein Engineering (ADPE), Merck Healthcare KGaA, Darmstadt, Germany; Biomolecular Immunotherapy, Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany. Electronic address: stefan.zielonka@tu-darmstadt.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor (TNF) is a key mediator of inflammation, acting as a proinflammatory cytokine with context-dependent dual roles. Here, we describe detailed assays to investigate key downstream signaling pathways of TNF involved in either cell death induction or NF-κB-mediated pro-survival signaling via the TNFR1 axis. We describe steps for target cell and reagent preparation, cell stimulation for cell death induction, and detection of activated intracellular signaling proteins by flow cytometry. For complete details on the use and execution of this protocol, please refer to Unmuth et al.

Indexed as

AntibodyBiotechnology and bioengineeringFlow CytometryImmunology

Identifiers

PMID42585014
PMCPMC13487824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.